Document is current
Any future updates will be listed below
-
Authors
Kargaran, Parisa K.
Garmany, Armin
Garmany, Ramin
Stutzman, Marissa J.
Sadeghian, Maryam
Ackerman, Michael J.
Perez-Terzic, Carmen M.
Terzic, Andre
Behfar, Atta
-
Funding
Funding for this research was provided by:
Van Cleve Cardiac Regenerative Program
National Institute of General Medical Sciences (T32 GM145408, T32 GM145408)
National Institutes of Health (R01 HL134664)
Marriott Family Foundation
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 7 April 2025
First Online: 24 April 2025
Declarations
:
: A.B., and A.T. are co-inventors on regenerative sciences related intellectual property previously disclosed to Mayo Clinic. Mayo Clinic, A.B., and A.T. have interests in Rion LLC. M.J.A has received consulting fees from Abbott, BioMarin Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Illumina, Invitae, Medtronic, Tenaya Therapeutics, and UpToDate; and with Mayo Clinic has license agreements with AliveCor, Anumana, ARMGO Pharma, Pfizer, and Thryv Therapeutics. None of these entities were involved in this study. All other authors have no conflicts of interest to disclose.
